Company: AEMD
Filing Date: 2025-08-20
Form Type: S-1
Source: 0001683168-25-006352
Chunk: 60

Company: AETHLON MEDICAL INC
Filing Date: 2025-08-20
Form: S-1
Chunk 60
---
 portion of the warrant if the holder (together with its affiliates and certain related
parties) would beneficially own in excess of 4.99% (or, upon election of the holder, 9.99%) of the number of shares of our common stock
outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of
the warrants. However, any holder may increase or decrease such percentage, provided that any increase will not be effective until the
61st day after notice of such election is provided to us.

Exercise Price. The
warrants will have an exercise price of $ per
share. The exercise price is subject to appropriate adjustment in the event of certain stock dividends and distributions, stock splits,
stock combinations, reclassifications or similar events affecting our common stock and also upon any distributions of assets, including
cash, stock or other property to our stockholders.

| 35 |

Transferability. Subject
to applicable laws, the warrants may be offered for sale, sold, transferred or assigned without our consent.

Exchange Listing. There
is no established trading market for the warrants and we do not expect a market to develop. In addition, we do not intend to apply for
the listing of the warrants on any national securities exchange or other trading market. Without an active trading market, the liquidity
of the warrants will be limited.

Fundamental Transactions. If
a fundamental transaction occurs, then the successor entity will succeed to, and be substituted for us, and may exercise every right and
power that we may exercise and will assume all of our obligations under the warrants with the same effect as if such successor entity
had been named in the warrant itself. If holders of our common stock are given a choice as to the securities, cash or property to be received
in a fundamental transaction, then the holder shall be given the same choice as to the consideration it receives upon any exercise of
the warrant following such fundamental transaction. In addition, in the event of a fundamental transaction which is within our control
and approved by our Board of Directors, the holders of warrants have the right to require us or a successor entity to redeem the warrant
for cash in the amount of the Black-Scholes value of the unexercised portion of the warrant on the date of the consummation of the fundamental
transaction. In the event of a fundamental transaction which is not within our control or approved by our Board of Directors, the holders
of the warrants shall only